Eyyup Cavdar

Prof. Eyyup Cavdar

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2022 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
ECEyyup Cavdar
Eyyup Cavdar
YIYakup Iriagac
Yakup Iriagac
KKKubilay Karaboyun
Kubilay Karaboyun
OAOkan Avci
Okan Avci
ESErdoğan Selcuk Seber
Erdoğan Selcuk Seber

26 June 2025 in Medicina
Verified
Journal Article
Open access
PDF file
ÖAÖzkan Alan
Özkan Alan
TTTugba Akın Telli
Tugba Akın Telli
SASinem Akbas
Sinem Akbas
SISelver Işık
Selver Işık
ECEyyup Cavdar
Eyyup Cavdar
PYPerran Fulden Yumuk
Perran Fulden Yumuk
Background and Objectives: Despite advances in immunotherapy, predicting survival outcomes in patients with non-small-cell lung cancer (NSCLC) remains challenging. Inflammatory and nutritional indices such as the Prognostic Nutritional Index (PNI), Geriatric Nutritional Risk Index (GNRI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Inflammatory Burden Index (IBI) have emerged as promising prognostic markers associated with overall survival (OS) in NSCLC patients. Materials and Methods: We retrospectively analyzed a total of 196 NSCLC patients treated with second-line nivolumab across multiple centers in Turkey. Of these, 101 patients aged ≥ 65 years were included in the elderly subgroup analysis. PNI, GNRI (in patients aged ≥ 65), and inflammation-based indices were calculated using pre-treatment laboratory values. ROC analysis determined optimal cut-off values. The Kaplan–Meier method and Cox proportional hazards models were used for survival analysis. Results: Median overall survival (OS) was 12.9 months in the full cohort and 12.1 months in patients aged ≥ 65. In univariate analysis, ECOG performance status (0–1), lower NLR (<3.3), lower PLR (<196.8), higher PNI (≥45.2), and higher GNRI (≥98.0) were significantly associated with longer OS. However, in the multivariate analysis adjusted for ECOG PS, NLR, PLR, and GNRI, only PNI remained an independent prognostic factor for OS in both the overall cohort [HR: 0.49, 95% CI: 0.26–0.92; p = 0.02] and elderly patients [HR: 0.45, 95% CI: 0.24–0.84; p = 0.01]. PNI is an independent prognostic biomarker for OS in NSCLC patients treated with immune checkpoint inhibitors. Conclusions: These findings support incorporating simple, cost-effective nutritional indices into clinical decision-making, particularly in elderly patients with NSCLC.

1 January 2022 in Contemporary Oncology
Verified
Journal Article
Open access
OAOkan Avci
Okan Avci
ECEyyup Cavdar
Eyyup Cavdar
YIYakup İriağaç
Yakup İriağaç
KKKubilay Karaboyun
Kubilay Karaboyun
ACAliye Celikkol
Aliye Celikkol
EŞErdoğan Selçuk Şeber
Erdoğan Selçuk Şeber
Introduction Although early diagnosis of breast cancer (BC) is often associated with a good prognosis, there is currently no biomarker with high sensitivity serving this purpose. B7H3, a recently identified member of the B7 family, appears to inhibit antitumor immunity. We investigated the...

1 November 2022 in Journal of the College of Physicians and Surgeons Pakistan
Verified
Journal Article
Closed access
ECEyyup Cavdar
Eyyup Cavdar
YIYakup Iriagac
Yakup Iriagac
OAOkan Avci
Okan Avci
ESErdogan Selcuk Seber
Erdogan Selcuk Seber
Objective: To evaluate the strongest prognostic factors in advanced gastric cancer. Study Design: Observational study. Place and Duration of Study: Department of Medical Oncology, Tekirdag Namik Kemal University, Tekirdag, Turkey, between March 2012 and April 2022. Methodology: Adult patients with metastatic cancer who had completed at least two months of chemotherapy, without any other comorbidity were included. Using Kaplan-Meier methodology and Cox regression methods, potential prognostic factors were analysed for overall survival. Two different models were created for multivariate analysis by using statistically significant factors in univariate analysis. Results: The median overall survival in 216 patients was 7.8 months. The univariate analysis showed that body-mass index, performance status, liver metastasis, albumin, gamma-glutamyl transferase, carcinoembryonic antigen, carbohydrate antigen (CA 19-9), neutrophil-lymphocyte ratio (NLR), systemic immune-inflammation index, albumin-to-alkaline phosphatase ratio, sodium-globulin ratio (SGR) prognostic nutritional index (PNI), albumin-bilirubin ratio, and albumin-globulin ratio were associated with survival. In Model 1, which included only laboratory indices, multivariate analyses revealed that NLR (p= 0.001), SGR (p=0.025), and PNI (p=0.032) were prognostic for overall survival. In Model 2, established with all parameters, NLR (p=0.003), albumin (p=0.003), performance status (p<0.001), and CA 19-9 (p<0.001) were found to be independent prognostic factors. Conclusion: Pretreatment NLR, SGR, PNI, albumin, performance status, and CA 19-9 are strong prognostic factors in patients with advanced gastric cancer. These prognostic factors, which are easily accessible in clinical practice, may be utilised as useful tools for clinicians.

5 June 2024 in Asia-Pacific Journal of Clinical Oncology
Verified
Journal Article
Closed access
ECEyyup Cavdar
Eyyup Cavdar
KKKubilay Karaboyun
Kubilay Karaboyun
KKKaan Kara
Kaan Kara

11 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
SYSEDAT YILDIRIM
SEDAT YILDIRIM
ADAkif Doğan
Akif Doğan
GAGoncagül Akdağ
Goncagül Akdağ
ECEyyup Cavdar
Eyyup Cavdar
OKOğuzcan Kınıkoğlu
Oğuzcan Kınıkoğlu
NTNedim Turan
Nedim Turan
Objective: Immunotherapies are commonly employed for the treatment of non-small-cell lung cancer (NSCLC). However, predictive biomarkers still need to be improved to predict responses to these agents. The lymphocyte–albumin (LA) laboratory index has not been evaluated before in this patient group. The aim of this study was to analyze the relation between the LA index and the survival rate of metastatic NSCLC patients who had immunotherapy after at least one round of chemotherapy. Methods: The research included 227 patients diagnosed with metastatic NSCLC, who were administered nivolumab after at least one round of chemotherapy. The LA index was calculated by multiplying lymphocyte count and albumin concentration. The optimal threshold values for the index were established by the examination of the ROC curve for both overall survival (OS) and progression-free survival (PFS). Oncological data were obtained retrospectively from patient files, and survival analyses were performed. Results: The median follow-up was 7.9 months. Progression was observed in 129 (56.9%) patients. A total of 97 (42.7%) patients died during the follow-up. The cutoff values of the LA index to predict OS and PFS were determined as 52.87 and 57.67, respectively. The low-LA group had significantly lowered OS and PFS compared to the high-LA group. LA was found to be an independent prognostic factor for PFS (hazard ratio 4.47; 95% confidence interval, 2.73–7.34; p < 0.001) and OS (hazard ratio 6.24; 95% confidence interval, 3.46–11.25; p < 0.001) in the multivariate regression analysis. Conclusions: In this study, we observed that the LA index independently predicts OS and PFS in immunotherapy-treated metastatic NSCLC patients. Its ease of application, low cost, and noninvasive nature make it a potential guide for clinicians in predicting treatment responses and survival.